Ticagrelor reduced leukocytes with attached platelets and interleukin-6 in patients with pneumonia, and decreased the requirement for supplemental oxygen.
RCT
Does ticagrelor reduce thromboinflammatory markers and improve lung function in patients with pneumonia?
Ticagrelor reduces thromboinflammatory markers and may improve lung function in patients with pneumonia, suggesting a potential therapeutic role for P2Y12 inhibition in sepsis and pneumonia.
Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y12 receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor XANTHIPPE; NCT01883869)
Sexton et al. (Wed,) conducted a rct in Pneumonia. Ticagrelor was evaluated on Leukocytes with attached platelets and interleukin (IL)-6. Ticagrelor reduced leukocytes with attached platelets and interleukin-6 in patients with pneumonia, and decreased the requirement for supplemental oxygen.